C. A. Martens, K. Wistuba-hamprecht, M. Maio, J. D. Wolchok, G. Pawelec et al., Weide Acquisition of data (provided animals, acquired and managed patients, provided facilities Weide Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A Weide Writing, review, and/or revision of the manuscript Weide Administrative, technical, or material support (i.e., reporting or organizing data Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, vol.364, pp.2517-2543, 2011.

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466

D. Schadendorf, F. Hodi, C. Robert, J. Weber, K. Margolin et al., Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, Journal of Clinical Oncology, vol.33, issue.17, 20159.
DOI : 10.1200/JCO.2014.56.2736

C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz et al., Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib, New England Journal of Medicine, vol.372, issue.1, pp.30-39, 2015.
DOI : 10.1056/NEJMoa1412690
URL : http://www.zora.uzh.ch/107163/1/Robert%20C%20et%20al.%20-%20N%20Engl%20J%20Med%202014.pdf

C. Robert, A. Ribas, J. Wolchok, F. Hodi, O. Hamid et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, issue.9948, pp.1109-1126, 2014.
DOI : 10.1016/S0140-6736(14)60958-2

P. Ascierto, M. Kalos, D. Schaer, M. Callahan, and J. Wolchok, Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types, Clinical Cancer Research, vol.19, issue.5, pp.1009-1029, 2013.
DOI : 10.1158/1078-0432.CCR-12-2982

P. Attia, G. Phan, A. Maker, M. Robinson, M. Quezado et al., Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti???Cytotoxic T-Lymphocyte Antigen-4, Journal of Clinical Oncology, vol.23, issue.25, pp.6043-53, 2005.
DOI : 10.1200/JCO.2005.06.205

S. Downey, J. Klapper, F. Smith, J. Yang, R. Sherry et al., Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade, Clinical Cancer Research, vol.13, issue.22, pp.6681-6689, 2007.
DOI : 10.1158/1078-0432.CCR-07-0187

E. Simeone, G. Gentilcore, D. Giannarelli, A. Grimaldi, C. Caraco et al., Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma, Cancer Immunology, Immunotherapy, vol.60, issue.7, pp.675-83, 2014.
DOI : 10.1007/s00262-014-1545-8

S. Kitano, M. Postow, C. Ziegler, D. Kuk, K. Panageas et al., Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes, Cancer Immunology Research, vol.2, issue.8, pp.812-833, 2014.
DOI : 10.1158/2326-6066.CIR-14-0013

S. Kelderman, B. Heemskerk, H. Van-tinteren, R. Van-den-brom, G. Hospers et al., Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma, Cancer Immunology, Immunotherapy, vol.369, issue.2, pp.449-58, 2014.
DOI : 10.1007/s00262-014-1528-9

J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel et al., Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Annals of Oncology, vol.24, issue.6, pp.1697-703, 2013.
DOI : 10.1093/annonc/mdt027

D. Giacomo, A. Danielli, R. Calabro, L. Bertocci, E. Nannicini et al., Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy), Cancer Immunology, Immunotherapy, vol.37, issue.4, pp.467-77, 2011.
DOI : 10.1007/s00262-010-0958-2

D. Hannani, M. Vetizou, D. Enot, S. Rusakiewicz, N. Chaput et al., Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25, Cell Research, vol.63, issue.2, pp.208-232, 2015.
DOI : 10.4161/cbt.21782

H. Braumuller, T. Wieder, E. Brenner, S. Assmann, M. Hahn et al., T-helper-1-cell cytokines drive cancer into senescence, Nature, vol.192, issue.7437, pp.361-366, 2013.
DOI : 10.1038/nature11824

P. Kvistborg, C. Shu, B. Heemskerk, M. Fankhauser, C. Thrue et al., T cell compartment in melanoma patients, OncoImmunology, vol.9, issue.4, pp.409-427, 2012.
DOI : 10.1073/pnas.89.8.3429

J. Yuan, M. Adamow, B. Ginsberg, T. Rasalan, E. Ritter et al., Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab, Proceedings of the National Academy of Sciences, vol.108, issue.40, pp.16723-16731, 2011.
DOI : 10.1073/pnas.1110814108

B. Weide, H. Zelba, E. Derhovanessian, A. Pflugfelder, T. Eigentler et al., Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis, Journal of Clinical Oncology, vol.30, issue.15, pp.1835-1876, 2012.
DOI : 10.1200/JCO.2011.40.2271

A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J. Zaretsky et al., Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, New England Journal of Medicine, vol.371, issue.23, pp.2189-99, 2014.
DOI : 10.1056/NEJMoa1406498

N. Van-rooij, M. Van-buuren, D. Philips, A. Velds, M. Toebes et al., Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma, Journal of Clinical Oncology, vol.31, issue.32, pp.439-481, 2013.
DOI : 10.1200/JCO.2012.47.7521

S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, D. Smith et al., Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012.
DOI : 10.1056/NEJMoa1200690

J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian et al., Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-65, 2012.
DOI : 10.1056/NEJMoa1200694

S. Wilgenhof, D. Four, S. Vandenbroucke, F. Everaert, H. Salmon et al., Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma, Journal of Immunotherapy, vol.36, issue.3, pp.215-237, 2013.
DOI : 10.1097/CJI.0b013e31828eed39

G. Ku, J. Yuan, D. Page, S. Schroeder, K. Panageas et al., Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting, Cancer, vol.27, issue.22 pt 1, pp.1767-75, 2010.
DOI : 10.1002/cncr.24951

S. Valpione, C. Martinoli, P. Fava, S. Mocellin, L. Campana et al., Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab, European Journal of Cancer, vol.51, issue.14
DOI : 10.1016/j.ejca.2015.06.130

P. Ferrucci, S. Gandini, A. Battaglia, S. Alfieri, D. Giacomo et al., Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients, British Journal of Cancer, vol.102, issue.12, pp.1904-1914, 2015.
DOI : 10.1093/annonc/mdt161

W. Wang, D. Yu, A. Sarnaik, Y. B. Hall, M. Morelli et al., Biomarkers on melanoma patient T Cells associated with ipilimumab treatment, Journal of Translational Medicine, vol.10, issue.1, p.146, 2012.
DOI : 10.1002/eji.200939261
URL : http://doi.org/10.1186/1479-5876-10-146

D. Gabrilovich, S. Ostrand-rosenberg, and V. Bronte, Coordinated regulation of myeloid cells by tumours, Nature Reviews Immunology, vol.205, issue.4, pp.253-68, 2012.
DOI : 10.1038/nri3175

B. Weide, A. Martens, H. Zelba, C. Stutz, E. Derhovanessian et al., Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells, Clinical Cancer Research, vol.20, issue.6, pp.1601-1610, 2014.
DOI : 10.1158/1078-0432.CCR-13-2508

C. Meyer, L. Cagnon, C. Costa-nunes, P. Baumgaertner, N. Montandon et al., Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab, Cancer Immunology, Immunotherapy, vol.60, issue.10, pp.247-57, 2014.
DOI : 10.1007/s00262-013-1508-5

C. Gebhardt, A. Sevko, H. Jiang, R. Lichtenberger, M. Reith et al., Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab, Clinical Cancer Research, vol.21, issue.24, pp.5453-5462, 2015.
DOI : 10.1158/1078-0432.CCR-15-0676

C. Balch, J. Gershenwald, S. Soong, J. Thompson, M. Atkins et al., Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, issue.36, pp.6199-206, 2009.
DOI : 10.1200/JCO.2009.23.4799
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793035

R. Camp, M. Dolled-filhart, and D. Rimm, X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization, Clinical Cancer Research, vol.10, issue.21, pp.7252-7261, 2004.
DOI : 10.1158/1078-0432.CCR-04-0713

J. Wolchok, A. Hoos, O. Day, S. Weber, J. Hamid et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624

F. Harrell, . Jr, K. Lee, and D. Mark, MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, Statistics in Medicine, vol.15, issue.4, pp.361-87, 1996.
DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4

K. Schindler, K. Harmankaya, M. Postow, S. Frantal, D. Bello et al., Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody, ASCO Meeting Abstracts, vol.31, p.9024, 2013.

H. Schmidt, L. Bastholt, P. Geertsen, I. Christensen, S. Larsen et al., Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model, British Journal of Cancer, vol.72, issue.3, pp.273-281, 2005.
DOI : 10.1038/sj.bjc.6602702

N. Rochet, L. Kottschade, T. Grotz, L. Porrata, and S. Markovic, The Prognostic Role of the Preoperative Absolute Lymphocyte Count and Absolute Monocyte Count in Patients With Resected Advanced Melanoma, American Journal of Clinical Oncology, vol.38, issue.3, pp.252-260, 2015.
DOI : 10.1097/COC.0b013e31829b5605

Y. Mao, I. Poschke, E. Wennerberg, P. De-coana, Y. et al., Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2???Dependent Mechanisms, Cancer Research, vol.73, issue.13, pp.3877-87, 2013.
DOI : 10.1158/0008-5472.CAN-12-4115

J. Veltman, M. Lambers, M. Van-nimwegen, R. Hendriks, H. Hoogsteden et al., COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function, BMC Cancer, vol.18, issue.1, p.464464, 2010.
DOI : 10.1158/1055-9965.EPI-08-0705

P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano et al., Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function, The Journal of Experimental Medicine, vol.79, issue.12, pp.2691-702, 2006.
DOI : 10.1073/pnas.90.8.3539
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118163

A. Tarhini, H. Edington, L. Butterfield, Y. Lin, Y. Shuai et al., Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab, PLoS ONE, vol.72, issue.2, p.87705, 2014.
DOI : 10.1371/journal.pone.0087705.s007

L. Simson, J. Ellyard, L. Dent, K. Matthaei, M. Rothenberg et al., Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune Surveillance, The Journal of Immunology, vol.178, issue.7, pp.4222-4231, 2007.
DOI : 10.4049/jimmunol.178.7.4222

R. Carretero, I. Sektioglu, N. Garbi, O. Salgado, P. Beckhove et al., Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells, Nature Immunology, vol.62, issue.6, pp.609-626, 2015.
DOI : 10.1158/0008-5472.CAN-09-1627

D. Gabrilovich and S. Nagaraj, Myeloid-derived suppressor cells as regulators of the immune system, Nature Reviews Immunology, vol.172, issue.3, pp.162-74, 2009.
DOI : 10.1038/nri2506

S. Diem, B. Kasenda, J. Martin-liberal, A. Lee, D. Chauhan et al., Prognostic score for patients with advanced melanoma treated with ipilimumab, European Journal of Cancer, vol.51, issue.18, pp.2785-91, 2015.
DOI : 10.1016/j.ejca.2015.09.007

D. Altman, L. Mcshane, W. Sauerbrei, and S. Taube, Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration, PLoS Medicine, vol.362, issue.5, p.1001216, 2012.
DOI : 10.1371/journal.pmed.1001216.s001

A. Kotsakis, M. Harasymczuk, B. Schilling, V. Georgoulias, A. Argiris et al., Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples, Journal of Immunological Methods, vol.381, issue.1-2, pp.14-22, 2012.
DOI : 10.1016/j.jim.2012.04.004

P. Ascierto, E. Simeone, V. Sileni, J. Pigozzo, M. Maio et al., Clinical experience with ipilimumab 3??mg/kg: real-world efficacy and safety data from an expanded access programme cohort, Journal of Translational Medicine, vol.12, issue.1, p.116, 2014.
DOI : 10.1111/nyas.12180
URL : http://doi.org/10.1186/1479-5876-12-116

K. Schindler, K. Harmankaya, D. Kuk, J. Mangana, O. Michielin et al., Correlation of absolute and relative eosinophil counts with immunerelated adverse events in melanoma patients treated with ipilimumab, ASCO Meeting Abstracts, vol.32, p.9096, 2014.